CLASS II ONGOING Drug recall · Reported 5 Jun 2024 · FDA Enforcement Report

Metoprolol Tartrate Tablets USP, 25mg recalled

Rubicon Research Private is recalling Metoprolol Tartrate Tablets USP, 25mg, distributed nationwide in the US. The recall was initiated on 6 May 2024 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLot 231037H1, exp 6/2027

NDC52817-358, 52817-362, 52817-359, 52817-361, 52817-360

UPC0352817361103, 0352817361004, 0352817360106, 0352817362100, 0352817358509, 0352817359506

Quantity recalled11,664 Bottles

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number: D-0517-2024
FDA event ID: 94542
Recalling firm: Rubicon Research Private, Ambarnath
Brand: Metoprolol Tartrate
Manufacturer: TruPharma LLC
Classification: Class II
Status: Ongoing
Recall initiated: 6 May 2024
FDA classified: 29 May 2024
Reported: 5 Jun 2024
Type: Voluntary: Firm initiated
Reason category: Foreign Material
Drug class: Blood Pressure Medication

Timeline

6 May 2024	Recall initiated by company
29 May 2024	Classified by FDA	+23 days
5 Jun 2024	Published in enforcement report	+7 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Presence of Foreign Substance: metal in tablet

Foreign material recalls cover pieces of metal, plastic, glass, wood or other objects that got into the product during processing and could cause injury if eaten.

Product as listed by the FDA

Metoprolol Tartrate Tablets USP, 25mg, 1000 count bottle, Rx only, distributed by: TruPharma, LLC, Tampa, FL 33609, Manufactured by: Rubicon Research Private Limited, Ambernath Dist Thane 421506 India, NDC 52817-360-00

Where it was distributed

Nationwide

Questions about this recall

Why was it recalled?

Presence of Foreign Substance: metal in tablet

Which lots are affected?

Lot 231037H1, exp 6/2027

Where was it sold?

Nationwide

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Rubicon Research Private

All 4

Reported	Class	Recall	Company	Reason	Where
25 Sep 2024Drug	CLASS III	AcetaZOLAMIDE Tablets, USP, 125 mg bottled recalledAcetazolamide	Rubicon Research Private	Other	Nationwide
15 May 2024Drug	CLASS II	traMADol Hydrochloride Tablets, USP 50 mg recalledTramadol Hydrochloride	Rubicon Research Private	Other	Nationwide
19 Jan 2022Drug	CLASS II	Metoprolol Tartrate Tablets, USP 25 mg recalledMetoprolol Tartrate	Rubicon Research Private	Foreign Material	Nationwide

Other Metoprolol recalls

All 40

Reported	Class	Recall	Company	Reason	Where
20 May 2026Drug	CLASS II	Metoprolol Succinate Extended-Release Tablets, USP, 25 mg* recalledMetoprolol Succinate	Ascend Laboratories	Potency & Assay	Nationwide
11 Mar 2026Drug	CLASS II	Metoprolol Succinate Extended-Release Tablets recalledMetoprolol Succinate	Teva Pharmaceuticals USA	Potency & Assay	Nationwide
11 Mar 2026Drug	CLASS II	Metoprolol Succinate Extended-Release Tablets, 200 mg recalledMetoprolol Succinate	Teva Pharmaceuticals USA	Potency & Assay	Nationwide
11 Mar 2026Drug	CLASS II	Metoprolol Succinate Extended-Release Tablets, 25 mg bottles recalledMetoprolol Succinate	Teva Pharmaceuticals USA	Potency & Assay	Nationwide
11 Mar 2026Drug	CLASS II	Metoprolol Succinate Extended-Release Tablets, 50 mg bottles recalledMetoprolol Succinate	Teva Pharmaceuticals USA	Potency & Assay	Nationwide